KMED

KraneShares Emerging Market Healthcare Index ETF

Download KMED Presentation

Download Fact Sheet

Investment Strategy:

KMED seeks to provide investment results that, before fees and expenses, track the performance of the Solactive Emerging Markets Healthcare Index. The index seeks to track the equity market performance of companies engaged in the health care sector in various emerging markets. The issuers include small-cap, mid-cap, and large-cap companies involved in hospital management, healthcare management, pharmaceutical manufacturing, and biotechnology, among other sub-industries.

Emerging Market Healthcare Sector Highlights:

  • By 2040, emerging market countries on average are projected to increase healthcare spending as percent of GDP by 24.4% compared to just 9.8% in developed markets over the same time period1.
  • In emerging markets, rapid urbanization and rising income is fueling growth in the demand for healthcare services and treatments.
  • Cases of non-communicable diseases (NCDs) such as diabetes and cancer are rising steadily in emerging market countries, presenting a growth opportunity for innovators in the healthcare space.
  • Emerging markets governments are enacting policies such as India’s “National Health Protection Mission” and China’s “Healthy China 2030 Plan” to meet the growing demand for healthcare.

KMED features:

  • Exposure to the Emerging Market healthcare industry with a low correlation to US healthcare equities. Specifically: pharmaceuticals, biotechnology, healthcare administration services, and medical equipment.
  • Access to emerging market innovators in healthcare and pharmaceutical research.
  • Exposure to companies that benefit from the growing and aging EM populations.

1.) Dieleman, Joseph L et al., “Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries”, The Lancet , Volume 389 , Issue 10083 , 2005 - 2030.

Fund Details

Data as of 05/12/2021
TickerKMED
Primary ExchangeNYSE
CUSIP500767819
ISINUS5007678197
Net Assets$5,319,089
Total Annual Fund Operating Expense0.80%
Inception Date8/29/18
Distribution FrequencyAnnual

Daily Performance

Data as of 05/12/2021
Premium Discount Chart
NAV
Net Asset Value$35.46 
Daily Change0.47%
Price
Market Price$34.96 
Daily Change-1.41%
30 Day Median Bid/Ask Spread
Value0.59%

The ETF’s 30 Day Median Bid-Ask Spread is calculated by identifying the ETF’s national best bid and national best offer ("NBBO") as of the end of each 10 second interval during each trading day of the last 30 calendar days and dividing the difference between each such bid and offer by the midpoint of the NBBO. The median of those values is identified and that value is expressed as a percentage rounded to the nearest hundredth.

Performance History

Distributions
Cumulative %
Data as of: 04/30/2021
Fund NAVClosing PriceIndex
1 Month7.88%6.36%8.00%
3 Month0.50%-0.50%0.53%
6 Month17.62%16.83%18.35%
Since Inception46.59%45.69%50.09%
Avg Annualized %
Data as of month end: 04/30/2021
Fund NAVClosing PriceIndex
1 Year56.03% 57.88%58.12%
Since Inception15.39% 15.12%16.42%
Avg Annualized %
Data as of quarter end: 03/31/2021
Fund NAVClosing PriceIndex
1 Year60.18%61.48%62.23%
Since Inception12.57% 12.93%13.55%
Growth of $10,000
Data as of 05/12/2021

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

The Growth of $10,000 chart reflects an initial investment of $10,000 on the day prior to the selected time period and assumes reinvestment of dividends and capital gains. For the growth of $10,000 chart since inception, the initial investment of $10,000 is instead made on the inception date of the Fund. Fund expenses, including management fees and other expenses were deducted. The growth of a $10,000 investment in the fund is hypothetical and for illustration purposes only.

Top 10 Holdings

Data as of 05/12/2021
Full Holdings .CSV
RankCompany Name% of Net AssetsTickerIdentifierShares HeldMarket Value($)
1SHENZHEN MINDR-A5.12%300760CNE100003G673,900272,503
2SAMSUNG BIOLOGICS CO LTD4.16%207940KR7207940008291221,488
3CELLTRION INC3.62%068270KR7068270008826192,793
4SUN PHARMACEUTICAL INDUS3.53%SUNPINE044A0103619,601187,634
5CHONGQING ZHIF-A3.37%300122CNE100000V205,513179,421
6CHINA EVERGRANDE3.16%708HK000026459525,500167,952
7WUXI BIOLOGICS CAYMAN INC3.04%2269KYG97008117311,781161,711
8AIER EYE HSPTL-A2.91%300015CNE100000GR613,370154,836
9JIANGSU HENGRU-A2.85%600276CNE0000014W711,740151,332
10CELLTRION HEALTH2.36%091990KR70919900021,277125,469

Holdings are subject to change.